{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:05:20Z","timestamp":1790665520587,"version":"4.1.0"},"reference-count":105,"publisher":"MDPI AG","issue":"20","license":[{"start":{"date-parts":[[2021,10,14]],"date-time":"2021-10-14T00:00:00Z","timestamp":1634169600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Richter transformation (RT) is a poorly understood complication of chronic lymphocytic leukemia (CLL) with a dismal prognosis. It is associated with a switch in histopathology and biology, generally with a transformation of the original CLL clone to diffuse large B-cell lymphoma (DLBCL) or less frequently to Hodgkin\u2019s variant of Richter transformation (HVRT). It occurs in 2\u201310% of CLL patients, with an incidence rate of 0.5\u20131% per year, and may develop in treatment-na\u00efve patients, although it is more common following therapy. In recent years, there has been a deeper understanding of the molecular pathogenesis of RT that involves the inactivation of the TP53 tumor suppressor gene in 50\u201360% of cases and the activation of aberrations of NOTCH1 and MYC pathways in about 30% of cases. Compared to the preceding CLL, 80% of cases with DLBCL-RT and 30% of HVRT harbor the same IGHV-D-J rearrangements, indicating a clonal evolution of the disease, while the remaining cases represent de novo lymphomas that are clonally unrelated. Despite advances in understanding the molecular variations and the pathogenesis of the disease, there is still no significant improvement in patient outcomes. However, if no clinical trials were designed for patients with RT in the past, now there many studies for these patients that incorporate new drugs and novel combinations that are being explored. In this review, we summarize the new information accumulated on RT with special emphasis on results involving the novel therapy tested for this entity, which represents an unmet clinical need.<\/jats:p>","DOI":"10.3390\/cancers13205141","type":"journal-article","created":{"date-parts":[[2021,10,14]],"date-time":"2021-10-14T09:10:49Z","timestamp":1634202649000},"page":"5141","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Richter Transformation in Chronic Lymphocytic Leukemia: Update in the Era of Novel Agents"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3435-8612","authenticated-orcid":false,"given":"Tamar","family":"Tadmor","sequence":"first","affiliation":[{"name":"Hematology Unit, Bnai-Zion Medical Center, Haifa 3339419, Israel"},{"name":"The Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa 3525422, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8923-1467","authenticated-orcid":false,"given":"Ilana","family":"Levy","sequence":"additional","affiliation":[{"name":"Hematology Unit, Bnai-Zion Medical Center, Haifa 3339419, Israel"},{"name":"The Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa 3525422, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,10,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.3109\/10428194.2014.979411","article-title":"Richter syndrome in chronic lymphocytic leukemia: Updates on biology, clinical features and therapy","volume":"56","author":"Jamroziak","year":"2015","journal-title":"Leuk. Lymphoma"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"IJH09","DOI":"10.2217\/ijh-2018-0010","article-title":"Current trends in the management of Richter\u2019s syndrome","volume":"7","author":"Allan","year":"2019","journal-title":"Int. J. Hematol. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e235816","DOI":"10.1136\/bcr-2020-235816","article-title":"Transformation to plasmablastic lymphoma in CLL upon ibrutinib treatment","volume":"13","author":"Marvyin","year":"2020","journal-title":"BMJ Case Rep."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1200\/JCO.2005.05.0187","article-title":"Clinical outcomes and prognostic factors in patients with Richter\u2019s syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation","volume":"24","author":"Tsimberidou","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1111\/bjh.12458","article-title":"Diffuse large B-cell lymphoma (Richter syndrome) in patients with chronic lymphocytic leukaemia (CLL): A cohort study of newly diagnosed patients","volume":"162","author":"Parikh","year":"2013","journal-title":"Br. J. Haematol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"4415","DOI":"10.1158\/1078-0432.CCR-08-3266","article-title":"Stereotyped B-cell receptor is an independent risk factor of chronic lymphocytic leukemia transformation to richter syndrome","volume":"15","author":"Rossi","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0140-6736(07)61125-8","article-title":"Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): A randomised controlled trial","volume":"370","author":"Catovsky","year":"2007","journal-title":"Lancet"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"252","DOI":"10.3109\/10428194.2012.710327","article-title":"The impact of initial fludarabine therapy on transformation to Richter syndrome or prolymphocytic leukemia in patients with chronic lymphocytic leukemia: Analysis of an intergroup trial (CALGB 9011)","volume":"54","author":"Solh","year":"2013","journal-title":"Leuk. Lymphoma"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.ejca.2003.09.031","article-title":"Second malignancies and Richter\u2019s syndrome in patients with chronic lymphocytic leukaemia treated with cladribine","volume":"40","author":"Robak","year":"2004","journal-title":"Eur. J. Cancer"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1182\/blood-2015-06-651125","article-title":"Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: Updated results of the CLL8 trial","volume":"127","author":"Fischer","year":"2016","journal-title":"Blood"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1002\/ajh.25638","article-title":"Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma","volume":"94","author":"Munir","year":"2019","journal-title":"Am. J. Hematol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/S1470-2045(16)30212-1","article-title":"Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): A phase 2, open-label, multicentre study","volume":"17","author":"Jones","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S1470-2045(15)00465-9","article-title":"Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): A randomised, double-blind, phase 3 study","volume":"17","author":"Cramer","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1182\/blood-2016-06-719294","article-title":"Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia","volume":"129","author":"Ahn","year":"2017","journal-title":"Blood"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa1315226","article-title":"Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia","volume":"370","author":"Furman","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e114","DOI":"10.1016\/S2352-3026(17)30019-4","article-title":"Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: An open-label, randomised phase 3 trial","volume":"4","author":"Jones","year":"2017","journal-title":"Lancet Haematol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S1470-2045(16)30671-4","article-title":"Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: Interim results from a phase 3, randomised, double-blind, placebo-controlled trial","volume":"18","author":"Zelenetz","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"4527","DOI":"10.1158\/1078-0432.CCR-16-0955","article-title":"Venetoclax in patients with previously treated chronic lymphocytic leukemia","volume":"23","author":"Roberts","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/S1470-2045(16)30019-5","article-title":"Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: A multicentre, open-label, phase 2 study","volume":"17","author":"Stilgenbauer","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S1470-2045(17)30012-8","article-title":"Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: A phase 1b study","volume":"18","author":"Seymour","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","article-title":"Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia","volume":"373","author":"Burger","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1812836","article-title":"Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL","volume":"379","author":"Woyach","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1470-2045(18)30788-5","article-title":"Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): A multicentre, randomised, open-label, phase 3 trial","volume":"20","author":"Moreno","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1056\/NEJMoa1817073","article-title":"Ibrutinib\u2013Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia","volume":"381","author":"Shanafelt","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/S0140-6736(20)30262-2","article-title":"Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): A randomised, controlled, phase 3 trial","volume":"395","author":"Sharman","year":"2020","journal-title":"Lancet"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1182\/blood-2015-03-630947","article-title":"A phase 2 study of idelalisib plus rituximab in treatment-na\u00efve older patients with chronic lymphocytic leukemia","volume":"126","author":"Lamanna","year":"2015","journal-title":"Blood"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1182\/bloodadvances.2018030221","article-title":"Efficacy results of a phase 2 trial of first-line idelalisib plus ofatumumab in chronic lymphocytic leukemia","volume":"3","author":"Lampson","year":"2019","journal-title":"Blood Adv."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1056\/NEJMoa1815281","article-title":"Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions","volume":"380","author":"Fischer","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1007\/s00277-021-04603-y","article-title":"Outcomes of Richter\u2019s transformation of chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL): An analysis of the SEER database","volume":"100","author":"Elnair","year":"2021","journal-title":"Ann. Hematol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/s41375-020-0797-x","article-title":"Richter transformation in chronic lymphocytic leukemia (CLL)\u2014a pooled analysis of German CLL Study Group (GCLLSG) front line treatment trials","volume":"35","author":"Robrecht","year":"2021","journal-title":"Leukemia"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S1470-2045(14)71182-9","article-title":"Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: A phase 2, single-arm trial","volume":"16","author":"Farooqui","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/leu.2017.175","article-title":"Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL\/SLL","volume":"32","author":"Brown","year":"2018","journal-title":"Leukemia"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1365-2141.2008.07166.x","article-title":"Biological and clinical risk factors of chronic lymphocytic leukaemia transformation to Richter syndrome","volume":"142","author":"Rossi","year":"2008","journal-title":"Br. J. Haematol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/j.1365-2141.2008.07248.x","article-title":"Richter syndrome: A review of clinical, ocular, neurological and other manifestations","volume":"142","author":"Omoti","year":"2008","journal-title":"Br. J. Haematol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1002\/hon.2502","article-title":"Clinical, pathological, and biological characterization of Richter syndrome developing after ibrutinib treatment for relapsed chronic lymphocytic leukemia","volume":"36","author":"Innocenti","year":"2018","journal-title":"Hematol. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/j.1365-2141.2007.06801.x","article-title":"Risk factors for development of a second lymphoid malignancy in patients with chronic lymphocytic leukaemia","volume":"139","author":"Slager","year":"2007","journal-title":"Br. J. Haematol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.leukres.2004.09.008","article-title":"Richter\u2019s transformation of chronic lymphocytic leukemia: The possible role of fludarabine and the Epstein-Barr virus in its pathogenesis","volume":"29","author":"Thornton","year":"2005","journal-title":"Leuk. Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1182\/blood-2013-11-516229","article-title":"How we treat Richter syndrome","volume":"123","author":"Parikh","year":"2014","journal-title":"Blood"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1007\/s11899-014-0223-4","article-title":"Risk Factors for Richter Syndrome in Chronic Lymphocytic Leukemia","volume":"9","author":"Parikh","year":"2014","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/sj.leu.2403249","article-title":"Relationship between the mutational status of VH genes and pathogenesis of diffuse large B-cell lymphoma in Richter\u2019s syndrome","volume":"18","author":"Csernus","year":"2004","journal-title":"Leukemia"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2019\/9870494","article-title":"Lymphomatoid Granulomatosis in a Patient with Chronic Lymphocytic Leukemia and Rapidly Progressing Peribronchovascular Pulmonary Infiltrates","volume":"2019","author":"Rezvani","year":"2019","journal-title":"Case Rep. Pulmonol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1182\/blood-2010-09-302174","article-title":"The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation","volume":"117","author":"Rossi","year":"2011","journal-title":"Blood"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1038\/leu.2008.399","article-title":"Telomere length is an independent predictor of survival, treatment requirement and Richter\u2019s syndrome transformation in chronic lymphocytic leukemia","volume":"23","author":"Rossi","year":"2009","journal-title":"Leukemia"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1182\/blood-2020-136605","article-title":"Complex Karyotype Subtypes at Chronic Lymphocytic Leukemia Diagnosis Refine the Risk of Developing a Richter Syndrome. The Richter Syndrome Scoring System","volume":"136","author":"Visentin","year":"2020","journal-title":"Blood"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Visentin, A., Bonaldi, L., Rigolin, G.M., Mauro, F.R., Martines, A., Frezzato, F., Pravato, S., Gargarella, L.R., Bardi, M.A., and Cavallari, M. (2021). The complex karyotype landscape in chronic lymphocytic leukemia allows to refine the risk of Richter syndrome transformation. Haematologica.","DOI":"10.3324\/haematol.2021.278304"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1182\/blood-2013-03-489518","article-title":"Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome","volume":"122","author":"Chigrinova","year":"2013","journal-title":"Blood"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/j.1365-2141.2012.09155.x","article-title":"Different impact of NOTCH1 and SF3B1 mutations on the risk of chronic lymphocytic leukemia transformation to Richter syndrome","volume":"158","author":"Rossi","year":"2012","journal-title":"Br. J. Haematol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1182\/blood.2020005734","article-title":"Active Akt signaling triggers CLL toward Richter transformation via overactivation of Notch1","volume":"137","author":"Kohlhaas","year":"2021","journal-title":"Blood"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"3413","DOI":"10.1158\/0008-5472.CAN-17-4004","article-title":"Novel richter syndrome xenograft models to study genetic architecture, biology, and therapy responses","volume":"78","author":"Vaisitti","year":"2018","journal-title":"Cancer Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.neo.2020.11.010","article-title":"U-RT1\u2013A new model for Richter transformation","volume":"23","author":"Schmid","year":"2021","journal-title":"Neoplasia"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1182\/blood.2020005650","article-title":"Genomic and transcriptomic correlates of Richter transformation in chronic lymphocytic leukemia","volume":"137","author":"Klintman","year":"2021","journal-title":"Blood"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"100824","DOI":"10.1016\/j.blre.2021.100824","article-title":"Revisiting Richter transformation in the era of novel CLL agents","volume":"49","author":"Petrackova","year":"2021","journal-title":"Blood Rev."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1182\/blood.2020008276","article-title":"B Cell Receptor signaling and genetic lesions in TP53 and CDKN2A\/CDKN2B cooperate in Richter Transformation","volume":"138","author":"Chakraborty","year":"2021","journal-title":"Blood"},{"key":"ref_54","first-page":"1","article-title":"Clinical, biological, and molecular genetic features of Richter syndrome and prognostic significance: A study of the French Innovative Leukemia Organization","volume":"34","author":"Moulin","year":"2021","journal-title":"Am. J. Hematol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"594841","DOI":"10.3389\/fimmu.2020.594841","article-title":"Microenvironment Remodeling and Subsequent Clinical Implications in Diffuse Large B-Cell Histologic Variant of Richter Syndrome","volume":"11","author":"Notarantonio","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/s41408-021-00477-5","article-title":"Distinct immune signatures in chronic lymphocytic leukemia and Richter syndrome","volume":"11","author":"Wang","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1111\/his.13024","article-title":"Diagnostic dilemmas of high-grade transformation (Richter\u2019s syndrome) of chronic lymphocytic leukaemia: Results of the phase II National Cancer Research Institute CHOP-OR clinical trial specialist haemato-pathology central review","volume":"69","author":"Soilleux","year":"2016","journal-title":"Histopathology"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"4574","DOI":"10.1182\/blood.V120.21.4574.4574","article-title":"Cell of Origin in Richter\u2019s Transformation of CLL","volume":"120","author":"Khan","year":"2012","journal-title":"Blood"},{"key":"ref_59","first-page":"1146","article-title":"Richter\u2019s transformation in chronic lymphocytic leukemia","volume":"26","author":"Jain","year":"2012","journal-title":"Oncology"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1007\/s00277-018-3390-x","article-title":"Diagnosis of Richter transformation in chronic lymphocytic leukemia: Histology tips the scales","volume":"97","author":"Federmann","year":"2018","journal-title":"Ann. Hematol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1182\/blood-2013-11-536169","article-title":"Correlation between FDG\/PET, histology, characteristics, and survival in 332 patients with chronic lymphoid leukemia","volume":"123","author":"Falchi","year":"2014","journal-title":"Blood"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00277-017-3149-9","article-title":"Approach to Richter transformation of chronic lymphocytic leukemia in the era of novel therapies","volume":"97","author":"Khan","year":"2018","journal-title":"Ann. Hematol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s11864-017-0512-y","article-title":"Treatment of Richter\u2019s Syndrome","volume":"18","author":"Condoluci","year":"2017","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1182\/blood-2018-01-791376","article-title":"Biology and treatment of Richter syndrome","volume":"131","author":"Rossi","year":"2018","journal-title":"Blood"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1097\/RLU.0000000000002879","article-title":"Prognostic Value of Baseline Total Metabolic Tumor Volume Measured on FDG PET in Patients with Richter Syndrome","volume":"45","author":"Pontoizeau","year":"2020","journal-title":"Clin. Nucl. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"e277","DOI":"10.1016\/j.clml.2020.12.003","article-title":"2-[18F]-FDG PET\/CT Role in Detecting Richter Transformation of Chronic Lymphocytic Leukemia and Predicting Overall Survival","volume":"21","author":"Albano","year":"2021","journal-title":"Clin. Lymphoma, Myeloma Leuk."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.crad.2021.06.001","article-title":"Chronic lymphocytic leukaemia and Richter\u2019s transformation: Multimodal review and new imaging paradigms","volume":"76","author":"Musanhu","year":"2021","journal-title":"Clin. Radiol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1200\/JCO.2007.11.8513","article-title":"Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter\u2019s syndrome or fludarabine- refractory chronic lymphocytic leukemia","volume":"26","author":"Tsimberidou","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.clml.2013.03.012","article-title":"Phase I-II clinical trial of oxaliplatin, fludarabine, cytarabine, and rituximab therapy in aggressive relapsed\/refractory chronic lymphocytic leukemia or Richter syndrome","volume":"13","author":"Tsimberidou","year":"2013","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"E239","DOI":"10.1002\/ajh.23841","article-title":"Poor efficacy and tolerability of R-CHOP in relapsed\/refractory chronic lymphocytic leukemia and Richter transformation","volume":"89","author":"Langerbeins","year":"2014","journal-title":"Am. J. Hematol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/bjh.14177","article-title":"NCRI phase II study of CHOP in combination with ofatumumab in induction and maintenance in newly diagnosed Richter syndrome","volume":"175","author":"Eyre","year":"2016","journal-title":"Br. J. Haematol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/bjh.15035","article-title":"A single-institution retrospective cohort study of first-line R-EPOCH chemoimmunotherapy for Richter syndrome demonstrating complex chronic lymphocytic leukaemia karyotype as an adverse prognostic factor","volume":"180","author":"Rogers","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/ejh.12474","article-title":"Platinum and high-dose cytarabine-based regimens are efficient in ultra high\/high-risk chronic lymphocytic leukemia and Richter\u2019s syndrome: Results of a French retrospective multicenter study","volume":"95","author":"Durot","year":"2015","journal-title":"Eur. J. Haematol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"329","DOI":"10.3109\/10428190109064589","article-title":"Fractionated cyclophosphamide, vincristine, liposomal daunorubicin (daunoxome), and dexamethasone (hyperCVXD) regimen in Richter\u2019s syndrome","volume":"42","author":"Dabaja","year":"2001","journal-title":"Leuk. Lymphoma"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1002\/cncr.11238","article-title":"Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Rich","volume":"97","author":"Tsimberidou","year":"2003","journal-title":"Cancer"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"E218","DOI":"10.1002\/ajh.23826","article-title":"Richter\u2019s transformation to diffuse large B-cell lymphoma: A retrospective study reporting clinical data, outcome, and the benefit of adding rituximab to chemotherapy, from the Israeli CLL Study Group","volume":"89","author":"Tadmor","year":"2014","journal-title":"Am. J. Hematol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1200\/JCO.2011.37.4108","article-title":"Autologous and allogeneic stem-cell transplantation for transformed chronic lymphocytic leukemia (Richter\u2019s syndrome): A retrospective analysis from the Chronic Lymphocytic Leukemia Subcommittee of the Chronic Leukemia Working Party and Lymphoma Working P","volume":"30","author":"Cwynarski","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1182\/bloodadvances.2020003726","article-title":"Reduced-intensity conditioning hematopoietic stem cell transplantation for chronic lymphocytic leukemia and Richter\u2019s transformation","volume":"5","author":"Lahoud","year":"2021","journal-title":"Blood Adv."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1016\/j.clml.2017.10.002","article-title":"Allogeneic Hematopoietic Cell Transplantation for Richter Syndrome: A Single-Center Experience","volume":"18","author":"Kumar","year":"2018","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Kim, H.T., Baker, P.O., Parry, E., Davids, M., Alyea, E.P., Ho, V.T., Cutler, C., Koreth, J., Gooptu, M., and Romee, R. (2021). Allogeneic hematopoietic cell transplantation outcomes in patients with Richter\u2019s transformation. Haematologica.","DOI":"10.3324\/haematol.2021.279033"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.hemonc.2020.05.002","article-title":"Allogeneic hematopoietic cell transplantation is an effective treatment for patients with Richter syndrome: A systematic review and meta-analysis","volume":"14","author":"Aulakh","year":"2021","journal-title":"Hematol. Oncol. Stem Cell Ther."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1182\/blood-2014-12-610782","article-title":"The efficacy of ibrutinib in the treatment of Richter syndrome","volume":"125","author":"Tsang","year":"2015","journal-title":"Blood"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/bjh.15440","article-title":"BCR kinase inhibitors, idelalisib and ibrutinib, are active and effective in Richter syndrome","volume":"185","author":"Visentin","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1182\/blood-2014-12-617522","article-title":"Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: A phase 1b\/2 study","volume":"126","author":"Jaglowski","year":"2015","journal-title":"Blood"},{"key":"ref_85","first-page":"471","article-title":"Acalabrutinib Monotherapy Effective for Richter Transformation","volume":"19","author":"Hillmen","year":"2016","journal-title":"ASH Annu. Meet."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-019-5717-y","article-title":"The STELLAR trial protocol: A prospective multicentre trial for Richter\u2019s syndrome consisting of a randomised trial investigation CHOP-R with or without acalabrutinib for newly diagnosed RS and a single-arm platform study for evaluation of novel agents in","volume":"19","author":"Appleby","year":"2019","journal-title":"BMC Cancer"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","article-title":"Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma","volume":"35","author":"Davids","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1007\/s00277-021-04419-w","article-title":"Real-world outcomes following venetoclax therapy in patients with chronic lymphocytic leukemia or Richter syndrome: A FILO study of the French compassionate use cohort","volume":"100","author":"Bouclet","year":"2021","journal-title":"Ann. Hematol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"8004","DOI":"10.1200\/JCO.2020.38.15_suppl.8004","article-title":"A multicenter phase II study of venetoclax plus dose- adjusted R-EPOCH (VR- EPOCH) for Richter \u2019 s POPULAR","volume":"38","author":"Davids","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s11912-020-01001-x","article-title":"Richter Syndrome","volume":"23","author":"Condoluci","year":"2021","journal-title":"Curr. Oncol. Rep."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/bjh.15508","article-title":"Use of PD-1 (PDCD1) inhibitors for the treatment of Richter syndrome: Experience at a single academic centre","volume":"185","author":"Rogers","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"3419","DOI":"10.1182\/blood-2017-02-765685","article-title":"Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL","volume":"129","author":"Ding","year":"2017","journal-title":"Blood"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"e117","DOI":"10.1111\/bjh.16762","article-title":"Pembrolizumab in relapsed or refractory Richter syndrome","volume":"190","author":"Armand","year":"2020","journal-title":"Br. J. Haematol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1182\/blood-2018-99-120355","article-title":"A Phase II Trial of Nivolumab Combined with Ibrutinib for Patients with Richter Transformation","volume":"132","author":"Jain","year":"2018","journal-title":"Blood"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1080\/10428194.2018.1461862","article-title":"Rapid complete response to blinatumomab as a successful bridge to allogeneic stem cell transplantation in a case of refractory Richter syndrome","volume":"60","author":"Alderuccio","year":"2019","journal-title":"Leuk. Lymphoma"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1200\/JCO.2017.72.8519","article-title":"Durable molecular remissions in chronic lymphocytic leukemia treated with CD19-Specific chimeric antigen Receptor-modified T cells after failure of ibrutinib","volume":"35","author":"Turtle","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1182\/blood.2019002936","article-title":"Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure","volume":"135","author":"Gauthier","year":"2020","journal-title":"Blood"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1182\/blood-2020-138904","article-title":"Safety and Efficacy of CD19-CAR T Cells in Richter\u2019s Transformation after Targeted Therapy for Chronic Lymphocytic Leukemia","volume":"136","author":"Benjamini","year":"2020","journal-title":"Blood"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"4648","DOI":"10.1182\/bloodadvances.2020002783","article-title":"Clinical activity of axicabtagene ciloleucel in adult patients with Richter syndrome","volume":"4","author":"Kittai","year":"2020","journal-title":"Blood Adv."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1182\/blood-2020-138896","article-title":"A Once Daily, Oral, Triple Combination of BTK Inhibitor, mTOR Inhibitor and IMiD for Treatment of Relapsed\/Refractory Richter\u2019s Transformation and De Novo Diffuse Large B-Cell Lymphoma","volume":"136","author":"Mato","year":"2020","journal-title":"Blood"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/bjh.15514","article-title":"PD-1 is highly expressed by neoplastic B-cells in Richter transformation","volume":"185","author":"Behdad","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1182\/blood-2017-06-741058","article-title":"Redirecting T cells to hematological malignancies with bispecific antibodies","volume":"131","author":"Velasquez","year":"2018","journal-title":"Blood"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/cpt.1674","article-title":"CAR T-Cell Therapy in Hematologic Malignancies: A Voyage in Progress","volume":"107","author":"Holstein","year":"2020","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1182\/blood.2020008404","article-title":"ROR1 targeting with the antibody drug-conjugate VLS-101 is effective in Richter syndrome patient-derived xenograft mouse models","volume":"137","author":"Vaisitti","year":"2021","journal-title":"Blood"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1038\/s41375-021-01181-w","article-title":"BET proteolysis targeted chimera-based therapy of novel models of Richter Transformation-diffuse large B-cell lymphoma","volume":"35","author":"Fiskus","year":"2021","journal-title":"Leukemia"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/20\/5141\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:12:55Z","timestamp":1760166775000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/20\/5141"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,14]]},"references-count":105,"journal-issue":{"issue":"20","published-online":{"date-parts":[[2021,10]]}},"alternative-id":["cancers13205141"],"URL":"https:\/\/doi.org\/10.3390\/cancers13205141","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,14]]}}}